Krsnaa Diagnostics Peer Comparison

NSE: KRSNAA | BSE: 543328

₹554.85

₹-5.10 (-0.91%)

As on 01-Oct-2026IST

Market cap

₹1,798 Cr

Revenue (TTM)

₹815 Cr

P/E Ratio

18.5

P/B Ratio

1.8

Div. Yield

0.4 %

Edit

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Market cap (₹ Cr)	1,798	36,515	33,680	30,875	14,713
Revenue (₹ Cr)	815	4,683	2,891	4,213	857
Net Profit (₹ Cr)	97.53	552.34	546.30	190.80	187.49
Net Margin (%)	11.31	11.55	18.23	4.49	21.32
RoE (%)	10.24	14.93	23.03	9.45	20.58
Price to Earnings	18.45	65.65	62.15	151.12	78.47
Price-To-Book	1.82	8.88	12.89	8.16	14.61

Income Statement (₹ Cr)

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Operating Revenue	815.33	4,683.37	2,890.80	4,212.50	857.13
Total Income	862.01	4,783.78	2,995.90	4,248.00	879.41
Total Expenditure	596.87	3,704.62	2,053.10	3,379.70	495.19
EBITDA	218.46	978.75	837.70	832.80	361.94
Depreciation	96.78	246.41	171.60	330.60	96.06
EBIT	121.67	732.34	666.10	502.20	265.89
Interest	42.90	92.01	24.40	253.30	36.75
Other Income	46.68	100.41	105.10	35.50	22.28
Exceptional Items	0.00	-20.61	-30.10	-11.20	0.00
Profit before Tax	125.45	720.14	716.70	273.20	251.42
Provision for Tax	27.92	167.80	170.40	82.40	63.93
Profit after Tax	97.53	552.34	546.30	190.80	187.49

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Shareholder's Funds	980.39	3,961.57	2,508.20	2,247.40	957.15
Minority Interest	0.00	3.84	-4.40	9.90	0.00
Non-Current Liabilities	568.13	1,293.60	154.00	3,961.30	426.03
Current Liabilities	275.20	627.13	450.70	1,238.90	123.87
Total Liabilities	1,818.67	5,905.00	3,139.97	7,690.70	1,507.05

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Non-Current Assets	927.01	3,128.95	1,176.30	5,416.90	737.24
Current Assets	738.34	1,674.92	1,566.60	937.40	321.90
Total Assets	1,818.67	5,905.00	3,139.97	7,690.70	1,507.05
Total Debt*	490.51	631.08	0.00	3,244.00	0.00
Net Current Assets	463.14	1,047.79	1,115.90	-301.50	198.03
Contingent Liabilities	66.34	100.01	16.76	81.10	0.13

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Cash From Operating Activities	143.10	714.39	635.61	510.80	270.59
Cash Flow from Investing Activities	-395.99	-1,089.11	-421.86	-1,451.70	-174.22
Cash from Financing Activities	279.27	271.85	-263.57	940.30	-69.49
Net Cash Inflow / Outflow	26.38	-102.87	-49.83	-0.60	26.88

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
ROCE (%)	13.08	19.38	29.56	11.51	30.28
ROE (%)	10.24	14.93	23.03	9.45	20.58
ROA (%)	6.28	10.35	18.64	2.83	13.49
EBIT Margin (%)	14.92	15.64	23.04	11.92	31.02
Net Margin (%)	11.31	11.55	18.23	4.49	21.32
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Revenue Growth (%)	10.19	21.27	14.29	30.90	20.18
EBIT Growth (%)	10.24	0.94	15.64	-16.88	26.22
Net Profit Growth (%)	21.61	3.43	5.38	-52.81	24.27
EPS Growth (%)	21.09	2.70	-30.51	-42.60	23.44
Book Value Growth (%)	10.93	16.51	15.41	5.13	21.86

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Price / Earnings	18.45	63.76	47.07	139.13	78.33
Price / Book Value	1.82	8.88	12.89	8.16	14.61
Dividend Yield (%)	0.36	0.04	1.02	0.00	0.14
EV/EBITDA	8.83	36.80	38.61	40.86	39.87
Market Cap (₹ Cr)	1,690.37	25,841.07	22,015.15	24,901.98	8,864.05

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Debt to Equity	0.45	0.15	0.00	1.19	0.00
Short term debt to equity ratio	0.01	--	--	0.15	--
Current Ratio	2.68	2.67	3.48	0.76	2.60
Quick Ratio	2.59	2.54	3.38	0.68	2.56
Interest Coverage	3.92	8.83	30.37	2.08	7.84

	Krsnaa Diagnostics	Global Health	Dr. Lal Pathlabs	Krishna Institute	Vijaya Diagno
Debtors to sales (%)	36.24	8.78	3.83	13.16	2.43
Asset Turnover	0.53	0.88	0.99	0.62	0.62
Receivable days	135.38	29.09	13.13	44.38	7.98
Inventory Days	13.26	6.05	5.28	7.52	2.20
Payable days	163.42	80.04	118.67	133.54	136.27
Cash Conversion Cycle	-14.79	-44.90	-100.26	-81.64	-126.08

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.